Search Results – Inserm Transfert

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

BIO15170-T1

Drug Field of development:

Respiratory Disease Therapy Area:

Product Type of patent:

New antisense oligonucleotide targeting all cystic fibrosis patients

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis (CF). In particular, the present […]

BIO12380-T1

Drug Field of development:

Genetic Disorders Therapy Area:

Product Type of patent:

Exon skipping therapy of erythropoietic protoporphyria

The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the […]

CHIM13035-T1

Drug Field of development:

Prostate Cancer Therapy Area:

Product Type of patent:

Hydrophobically modified antisense oligonucleotides comprising a cetal

The present invention concerns an oligonucleotide modified by substitution at the 3’ or the 5’ end by at least triple alkyl chain or at least one […]

BIO14109-T1

Drug Field of development:

Neuropathic Pain Therapy Area:

Target Type of patent:

Lipid antisens oligonucleotide targeting fxyd2 as a therapeutic agent

The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. […]

147

56

310

46

Our Technology Offers

New antisense oligonucleotide targeting all cystic fibrosis patients

Exon skipping therapy of erythropoietic protoporphyria

Hydrophobically modified antisense oligonucleotides comprising a cetal

Lipid antisens oligonucleotide targeting fxyd2 as a therapeutic agent

You might also be interested in

Exon skipping therapy of erythropoietic

Hydrophobically modified antisense

New antisense oligonucleotide targeting all cystic

Lipid antisens oligonucleotide targeting fxyd2 as